UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 152

Sortiert nach

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

The New England journal of medicine, 2012-06, Vol.366 (26), p.2443-2454

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma

Journal of clinical oncology, 2013-01, Vol.31 (3), p.373-379

2013

Link zum Volltext

Verfügbarkeit prüfen

Management of Cutaneous Melanoma

The New England journal of medicine, 2004-09, Vol.351 (10), p.998-1012

2004

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5794-5799

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group

Journal of clinical oncology, 2008-12, Vol.26 (35), p.5748-5754

2008

Link zum Volltext

Verfügbarkeit prüfen

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

Journal of clinical oncology, 2008-02, Vol.26 (4), p.527-534

2008

Link zum Volltext

Verfügbarkeit prüfen

Arginase-producing myeloid suppressor cells in renal cell carcinoma patients : A mechanism of tumor evasion

Cancer research (Chicago, Ill.), 2005-04, Vol.65 (8), p.3044-3048

2005

Link zum Volltext

Verfügbarkeit prüfen

Molecular Pathways: Can Activin-like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors?

Clinical cancer research, 2014-06, Vol.20 (11), p.2838-2845

2014

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Journal of clinical oncology, 2004-03, Vol.22 (5), p.909-918

2004

Link zum Volltext

Verfügbarkeit prüfen

BRAF Mutations in Metanephric Adenoma of the Kidney

European urology, 2012-11, Vol.62 (5), p.917-922

2012

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis

Blood, 2001-11, Vol.98 (9), p.2720-2725

2001

Link zum Volltext

Verfügbarkeit prüfen

The raf inhibitor BAY 43-9006 (sorafenib) induces caspase- independent apoptosis in melanoma cells

Cancer research (Chicago, Ill.), 2006-02, Vol.66 (3), p.1611-1619

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

Clinical cancer research, 2009-12, Vol.15 (24), p.7711-7718

2009

Link zum Volltext

Verfügbarkeit prüfen

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Journal of clinical oncology, 2014-04, Vol.32 (10), p.1020-1030

2014

Link zum Volltext

Verfügbarkeit prüfen

Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma

Clinical cancer research, 2004-09, Vol.10 (18), p.6342S-6346s

2004

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial

Journal of clinical oncology, 2003-08, Vol.21 (16), p.3133-3140

2003

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

Cancer, 2014-06, Vol.120 (11), p.1695-1701

2014

Link zum Volltext

Verfügbarkeit prüfen

The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

Clinical cancer research, 2010-07, Vol.16 (14), p.3628-3638

2010

Link zum Volltext

Verfügbarkeit prüfen

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma

Journal of immunotherapy (1997), 2012-01, Vol.35 (1), p.66

2012

Link zum Volltext

Verfügbarkeit prüfen

Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings

Radiology, 2009-03, Vol.250 (3), p.793

2009

Link zum Volltext

Verfügbarkeit prüfen

High-Dose Interferon Alfa-2b Does Not Diminish Antibody Response to GM2 Vaccination in Patients With Resected Melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696

Journal of clinical oncology, 2001-03, Vol.19 (5), p.1430-1436

2001

Link zum Volltext

Verfügbarkeit prüfen

Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma

Journal of clinical oncology, 2007-05, Vol.25 (15), p.2078-2085

2007

Link zum Volltext

Verfügbarkeit prüfen

Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

Journal of clinical oncology, 2001-08, Vol.19 (16), p.3635-3648

2001

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

Journal of clinical oncology, 2001-08, Vol.19 (16), p.3622-3634

2001

Link zum Volltext

Verfügbarkeit prüfen

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Journal of clinical oncology, 1999-07, Vol.17 (7), p.2105-2116

1999

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 152

Suche als RSS-Feed

Aktive Filter

ThemaBiological And Medical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(150)
Mit Volltextzugriff
(131)

Publikationsform

Artikel
(150)
Tagungsberichte
(2)

Sprache

Englisch
(152)
Japanisch
(28)

Erscheinungsjahr

n.n

Thema

Medical Sciences
(142)
Life Sciences & Biomedicine
(132)
Science & Technology
(132)
Humans
(128)
Male
(85)
Female
(83)
Middle Aged
(74)
Oncology
(74)
Pharmacology. Drug Treatments
(70)
Aged
(57)
Adult
(56)
Antineoplastic Agents
(55)
Tumors
(42)
Immunotherapy
(34)
Nephrology. Urinary Tract Diseases
(26)
Dermatology
(25)
Tumors Of The Skin And Soft Tissue. Premalignant Lesions
(25)
Treatment Outcome
(24)
Immunology
(23)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma

Management of Cutaneous Melanoma

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

Arginase-producing myeloid suppressor cells in renal cell carcinoma patients : A mechanism of tumor evasion

Molecular Pathways: Can Activin-like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors?

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

BRAF Mutations in Metanephric Adenoma of the Kidney

Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis

The raf inhibitor BAY 43-9006 (sorafenib) induces caspase- independent apoptosis in melanoma cells

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma

Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma

Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings

High-Dose Interferon Alfa-2b Does Not Diminish Antibody Response to GM2 Vaccination in Patients With Resected Melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696

Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma

Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Aktive Filter

Suchergebnisse filtern